Global Liquid Biopsy Market

1 INTRODUCTION OF GLOBAL LIQUID BIOPSY MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL LIQUID BIOPSY MARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER
5.1 Overview
5.2 Circulating Tumor Cells
5.3 Circulating Tumor DNA (CTDNA)
5.4 Cell-Free DNA
5.5 Extracellular Vesicles (Evs)
5.6 Others

6 GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE
6.1 Overview
6.2 Assay Kits
6.3 Instruments
6.4 Services

7 GLOBAL LIQUID BIOPSY MARKET, BY END USER
7.1 Overview
7.2 Reference Laboratories
7.3 Hospitals and Physician Laboratories
7.4 Academic and Research Centers
7.5 Other End Users

8 GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION
8.1 Overview
8.2 Cancer Applications
8.2.1 Lung Cancer
8.2.2 Breast Cancer
8.2.3 Colorectal Cancer
8.2.4 Prostate Cancer
8.2.5 Liver Cancer
8.2.6 Other Cancers
8.3 Non-Cancer Applications

9 GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
9.1 Overview
9.2 Early Cancer Screening
9.3 Therapy Selection
9.4 Treatment Monitoring
9.5 Recurrence Monitoring

10 GLOBAL LIQUID BIOPSY MARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 â€" 2025

11 GLOBAL LIQUID BIOPSY MARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 Biocept, Inc.
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 Qiagen N.V.
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 Roche Diagnostics
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 Bio-Rad Laboratories, Inc.
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 Myriad Genetics, Inc
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Menarini-Silicon Biosystems
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 Trovagene, Inc.
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 Guardant Health, Inc.
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 Mdxhealth SA
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Developments

12.10 Genomic Health, Inc.
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Developments

12.11 Raindance Technologies, Inc
12.11.1 Overview
12.11.2 Financial Performance
12.11.3 Product Outlook
12.11.4 Key Developments
12.12 Thermo Fisher Scientific Inc.
12.12.1 Overview
12.12.2 Financial Performance
12.12.3 Product Outlook
12.12.4 Key Developments

12.13 Illumina, Inc.
12.13.1 Overview
12.13.2 Financial Performance
12.13.3 Product Outlook
12.13.4 Key Developments

13 Appendix
13.1 Related Reports